Analytical Data
-
基因名
PDE1A
- Application
-
别名
hCam-1; 61 kDa Cam-PDE; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P54750
-
表达区间
Gly2~Asp318
-
分子量
40kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PDE1A, or phosphodiesterase 1A, is an enzyme that plays a critical role in the hydrolysis of cyclic nucleotides, specifically cAMP and cGMP, thereby regulating various physiological processes, including cellular signaling, muscle contraction, and neuronal communication. Research into PDE1A has gained traction due to its involvement in several pathological conditions, such as cardiovascular diseases, neurodegenerative disorders, and certain types of cancer. Its dual substrate specificity has made it a candidate for therapeutic targeting, prompting the development of selective inhibitors that may offer benefits over broader PDE inhibitors by minimizing side effects. Additionally, the understanding of its structural dynamics and regulatory mechanisms is crucial for the design of such inhibitors. Recent advancements in recombinant protein technology have facilitated the expression and purification of PDE1A, allowing for detailed biochemical studies and the exploration of its interactions with other cellular molecules. Consequently, PDE1A serves not only as a valuable biomarker for disease states but also as a potential therapeutic target, making its research pivotal in the fields of pharmacology and molecular medicine.
